AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-03-27 pm EDT 5-day change 1st Jan Change
180.4 USD +0.65% Intraday chart for AbbVie Inc. +2.31% +16.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating MT
Deals of the day-Mergers and acquisitions RE
Sector Update: Health Care Stocks Decline Late Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Softer in Afternoon Trading MT
Top Midday News: Boeing CEO to Step Down; United Airlines to Face Tight FAA Scrutiny; Barclays Upgrades Disney to Overweight; EU Opens Probe Into Apple, Meta, and Google; China to Block Use of Intel, AMD Chips; Ericsson Announces 1,200 Job Cuts in Sweden MT
Global markets live: United Airlines, Qualcomm, Amazon, Nissan, Boeing... Our Logo
AbbVie to Acquire Landos Biopharma For About $137.5 Million; Landos Shares Jump MT
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie DJ
AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million DJ
AbbVie to Acquire Landos Biopharma for About $137.5 Million MT
AbbVie to Acquire Landos Biopharma for About $137.5 Million MT
AbbVie to buy Landos to expand pipeline of immunity-related illnesses RE
AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024. CI
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing MT
AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal DJ
AbbVie Gets US FDA's Full Approval for Ovarian Cancer Treatment MT
AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients CI
US FDA grants full approval to AbbVie's ovarian cancer therapy RE
Skin care company Galderma's shares open higher on stock market debut RE
Abbvie Insider Sold Shares Worth $10,539,508, According to a Recent SEC Filing MT
Global markets live: Super Micro Computer, Boeing, Vale, Tesla, Nvidia, Intel, Nasdaq... Our Logo
Repeat & Correct : Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale -- Update DJ
Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale -- Update DJ
Kenneth Steiner Submits a Shareholder Proposal to AbbVie CI
Chart AbbVie Inc.
More charts
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
180.4 USD
Average target price
183.9 USD
Spread / Average Target
+1.96%
Consensus
  1. Stock
  2. Equities
  3. Stock AbbVie Inc. - Nyse
  4. News AbbVie Inc.
  5. AbbVie : Reports Encouraging Data From Phase 2 Study of Imbruvica/Venclexta Combination